Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors
Arcellx, Inc. (ACLX)
Company Research
Source: Business Wire
-- Mr. Galligan and Ms. Myers bring decades of experience to the company board ---- Derek Yoon steps down from the Board of Directors -- REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the appointments of Andrew Galligan and Kristin Myers to its Board of Directors. Mr. Galligan is a proven financial executive who brings over three decades of strategic leadership experience to the Arcellx Board. Ms. Myers, a highly experienced healthcare industry executive, adds diverse expertise in operational execution, sales and marketing, and market access.“On the heels of our significant business progress in 2024, we are excited to welcome both Andrew and Kristin to the Arcellx Board of Directors as we continue to accelerate our development pipeline and organizational growth,” said Rami Elghandour, Arce
Show less
Read more
Impact Snapshot
Event Time:
ACLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACLX alerts
High impacting Arcellx, Inc. news events
Weekly update
A roundup of the hottest topics
ACLX
News
- Arcellx (NASDAQ:ACLX) had its "buy" rating reaffirmed by analysts at Canaccord Genuity Group Inc.. They now have a $130.00 price target on the stock.MarketBeat
- Arcellx (NASDAQ:ACLX) had its "buy" rating reaffirmed by analysts at Needham & Company LLC. They now have a $105.00 price target on the stock.MarketBeat
- Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma [Yahoo! Finance]Yahoo! Finance
- Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel's Opportunity in Relapsed or Refractory Multiple Myeloma [Yahoo! Finance]Yahoo! Finance
- Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple MyelomaBusiness Wire
ACLX
Earnings
- 11/5/25 - Miss
ACLX
Sec Filings
- 12/8/25 - Form 8-K
- 12/5/25 - Form SCHEDULE
- 11/17/25 - Form 4
- ACLX's page on the SEC website